GSK has announced the formation of Haleon, an independent consumer healthcare company.

Haleon will be a new global consumer health leader with a strong portfolio of category-leading brands such as Sensodyne, Voltaren, Panadol, and Centrum Business. Haleon plans to demerge and launch as a new business in mid-2022.

Haleon is the culmination of a series of successful investments and strategic changes in GSK’s consumer health business over the previous eight years, including the merging of Novartis and Pfizer’s consumer product portfolios. It has evolved into a very valuable and concentrated worldwide firm with yearly sales of around £10 billion.

Its brands are trusted by healthcare experts, customers, and people all over the world to improve people’s health and well-being. The £150 billion consumer healthcare market is seeing robust demand, owing to a growing emphasis on health and wellbeing, increasing demand from an aging population and the emerging middle class, and unmet consumer requirements. As a result, the company is well-positioned to make a positive influence on human health and to develop ahead of the market in the years ahead.

GSK, Haleon, Pharmaceutical

We use cookies to give you the best online experience. By agreeing you consent the use of cookies in accordance with our Privacy Statement and cookie settings in your Privacy Settings below.

Privacy Settings saved!
Privacy Settings

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

These cookies are necessary for the website to function and cannot be switched off in our systems.

In order to use this website we use the following technically required cookies
  • wordpress_test_cookie

Decline all Services
Accept all Services